Abstract
Background: Cancer treatments may impair pulmonary function, respiratory muscle strength, and activities of daily life (ADL) in breast cancer survivors.
Aim: The purpose was to investigate pulmonary function, respiratory muscle strength, and ADL performance in breast cancer survivors.
Methods: Fifteen breast survivors (15F, age: 60.9±8.70 years) who underwent mastectomy or completed chemotherapy and/or radiotherapy treatment, without any metastasis or active disease were included. Spirometric measurements were performed. Respiratory muscle strength was measured using a portable mouthpiece pressure device. The ADL performance was assessed using Glittre ADL test.
Results: The FEV1 was found to be 94.1±10.5% pred. The mean maximal inspiratory (MIP) and expiratory pressure (MEP) were 84.0±20.7 cmH2O and 101.9±26.2 cmH2O, respectively. The percentage of predicted of MIP and MEP were: 113.3±22.4% pred and 72.3±16.0% pred. The mean Glittre ADL test duration was 3.1±0.7 (2.3-4.1) minutes, which was lower than that of reference values.
Conclusions: Breast cancer survivors had reduced expiratory muscle strength and impaired functional capability determined with ADL duration compared to the reference values of healthy adults. Considering the negative influences of functional limitation on health status, the strategies are needed to reverse this to prevent further unfavorable outcomes.
Footnotes
Cite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA1162.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2019